Purified recombinant Human CD59

This recombinant monoclonal antibody can detects endogenous levels of CD59 protein.

CD59 MIC11 MIN1 MIN2 MIN3 MSK21

CD59 glycoprotein (1F5 antigen) (20 kDa homologous restriction factor) (HRF-20) (HRF20) (MAC-inhibitory protein) (MAC-IP) (MEM43 antigen) (Membrane attack complex inhibition factor) (MACIF) (Membrane inhibitor of reactive lysis) (MIRL) (Protectin) (CD antigen CD59)

CD59 ;
MIC11 ;
MIN1 ;
MIN2 ;
MIN3 ;
MSK21 ;
CD59 glycoprotein ;
1F5 antigen ;
20 kDa homologous restriction factor ;
HRF-20 ;
HRF20 ;
MAC-inhibitory protein ;
MAC-IP ;
MEM43 antigen ;
Membrane attack complex inhibition factor ;
MACIF ;
Membrane inhibitor of reactive lysis ;
MIRL ;
Protectin ;
CD59 ;
CD59 nanobody ;

This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction.This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly ofThis complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation.This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations inThis gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified forThis gene. [provided by RefSeq, Jul 2008]

Disease:Defects in CD59 are the cause of CD59 deficiency [MIM:612300].,Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.,The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes.,online information:CD59 mutation db,PTM:Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.,PTM:N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants.,similarity:Contains 1 UPAR/Ly6 domain.,subcellular location:Soluble form found in a number of tissues.,subunit:Interacts with T-cell surface antigen CD2.,

Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Soluble form found in a number of tissues.

Detected on umbilical veil endothelial cells (PubMed:162579). Detected in placenta (at protein level) (PubMed:169283). Detected on endothelial cells (PubMed:169283).